Plasmacytoid urothelial carcinoma is rare and aggressive, with poor outcomes and challenges in accurate staging. National and institutional data reveal discrepancies in chemotherapy use and disease ...

Objective: To investigate the optimal cut-off value of immunohistochemical marker Ki67 as a prognostic factor to predict the recurrence of non-muscle invasive bladder urothelial carcinoma (NMIBUC).

In this video, Fed Ghali, MD, highlights key findings from the study, “Evaluating Clinical Outcomes and the Role of Neoadjuvant Chemotherapy in Plasmacytoid Urothelial Carcinoma: Insights from a ...

Drug-induced hyponatremia is an adverse reaction with accelerated electrolyte disturbance. This study reported a rare case of delayed hyponatremia in a 68year-old female with recurrent upper tract ...

Five percent of newly diagnosed patients have metastatic disease. Metastatic urothelial carcinoma (mUC) is primarily treated with cisplatin-based chemotherapy, immunotherapy, targeted therapy, or ...